meningococcal polysaccharide vaccine (Menomune-A/C/Y/W-135, MenACWY-CRM, Menactra, MenACYW-D)

From Aaushi
Jump to navigation Jump to search
[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20]

Introduction

Menactra (MenACYW-D) no longer available[20]

Indications

Contraindications

does NOT provide protection against meningococcus serogroup B, 30% of invasive infection with Neisseria meningitidis in USA[13]

Dosage

Injection: single dose vials Warnings:

Pharmacokinetics

Adverse effects

Mechanism of action

More general terms

Additional terms

Component of

References

  1. ↑ Kaiser Permanente Northern California Regional Drug Formulary, 1998
  2. ↑ Neal KR et al BMJ 320:846 2000
  3. ↑ 3.0 3.1 Prescriber's Letter 10(4):21 2003
  4. ↑ 4.0 4.1 4.2 Prescriber's Letter 12(4): 2005 New Drug: Menactra (Meningococcal Polysaccharide Vaccine) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=210405&pb=PRL (subscription needed) http://www.prescribersletter.com
  5. ↑ 5.0 5.1 Journal Watch 25(7):59, 2005 Pichichero M, Casey J, Blatter M, Rothstein E, Ryall R, Bybel M, Gilmet G, Papa T. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide- diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children. Pediatr Infect Dis J. 2005 Jan;24(1):57-62. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15665711
  6. ↑ 6.0 6.1 MedWatch, FDA http://www.fda.gov/medwatch/safety/2005/safety05.htm#Menactra
  7. ↑ 7.0 7.1 Centers for Disease Control and Prevention (CDC). Guillain-Barre syndrome among recipients of Menactra meningococcal conjugate vaccine-United States, June-July 2005. MMWR Morb Mortal Wkly Rep. 2005 Oct 14;54(40):1023-5. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16224452
    Prescriber's Letter 12(9): 2005 Guillain-Barre syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, June-July 2005. Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=211104&pb=PRL (subscription needed) http://www.prescribersletter.com
  8. ↑ 8.0 8.1 8.2 Vu DM, Welsch JA, Zuno-Mitchell P, Dela Cruz JV, Granoff DM. Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine. J Infect Dis. 2006 Mar 15;193(6):821-8. Epub 2006 Feb 8. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16479517
  9. ↑ Notice to Readers: Limited Supply of Meningococcal Conjugate Vaccine, Recommendation to Defer Vaccination of Persons Aged 11-12 Years MMWR Morb Mortal Wkly ReMay 19, 2006 / 55(Dispatch);1 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm55d520a1.htm
    Prescriber's Letter 13(8): 2006 Limited Supply of Meningococcal Conjugate Vaccine, Recommendation to Defer Vaccination of Persons Aged 11-12 Years Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=220805&pb=PRL (subscription needed) http://www.prescribersletter.com
  10. ↑ 10.0 10.1 FDA MedWatch http://www.fda.gov/medwatch/safety/2006/safety06.htm#Menactra
  11. ↑ Centers for Disease Control Revised Recommendations of the Advisory Committee on Immunization Practices to Vaccinate All Persons Aged 11- 18 Years with Meningococcal Conjugate Vaccine MMWR 56(31);794-795 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/17694617 <Internet> http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5631a3.htm
  12. ↑ 12.0 12.1 Prescriber's Letter 14(9): 2007 Immunization Update 2007 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=230923&pb=PRL (subscription needed) http://www.prescribersletter.com
  13. ↑ 13.0 13.1 13.2 Medical Knowledge Self Assessment Program (MKSAP) 14, 15 American College of Physicians, Philadelphia 2006, 2009
  14. ↑ Centers for Disease Control and Prevention (CDC) Updated Recommendation from the Advisory Committee on Immunization Practices (ACIP) for Revaccination of Persons at Prolonged Increased Risk for Meningococcal Disease MMWR September 25, 2009 / 58(37);1042-1043 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5837a4.htm
    Prescriber's Letter 16(12): 2009 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=251226&pb=PRL New Recommendations for Revaccination of Patients at High-Risk for Meningococcal Disease (subscription needed) http://www.prescribersletter.com
  15. ↑ Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Report (MMWR) MMWR: March 12, 2010, 59(09);273 Licensure of a Meningococcal Conjugate Vaccine (Menveo) and Guidance for Use --- Advisory Committee on Immunization Practices (ACIP), 2010 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/20224545 <Internet> http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5909a5.htm
  16. ↑ 16.0 16.1 Advisory Committee on Immunization Practices Revised Recommendations of the Advisory Committee on Immunization Practices to Vaccinate All Persons Aged 11- 18 Years with Meningococcal Conjugate Vaccine http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5631a3.htm
  17. ↑ 17.0 17.1 17.2 17.3 Centers for Disease Control and Prevention (CDC) Updated Recommendations for Use of Meningococcal Conjugate Vaccines - Advisory Committee on Immunization Practices (ACIP), 2010 Morbidity and Mortality Weekly Report (MMWR) January 28, 2011 / 60(03);72-76 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/21270745 <Internet> http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6003a3.htm
  18. ↑ 18.0 18.1 FDA NEWS RELEASE: April 22, 2012 FDA approves the first vaccine to prevent meningococcal disease in infants and toddlers http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm252392.htm
  19. ↑ Prescriber's Letter 19(1): 2012 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=280118&pb=PRL Meningococcal Disease: Who Should be Vaccinated? (subscription needed) http://www.prescribersletter.com
  20. ↑ 20.0 20.1 Wodi AP et al. Advisory committee on immunization practices recommended immunization schedule for children and adolescents aged 18 years or younger - United States, 2024. MMWR Morb Mortal Wkly Rep 2024 Jan 11; 73:6 https://www.cdc.gov/mmwr/volumes/73/wr/mm7301a2.htm
    American Academy of Pediatrics, Committee on Infectious Diseases. Recommended childhood and adolescent immunization schedule: United States, 2024. Pediatrics 2024 Feb; 153:e2023065044 https://publications.aap.org/pediatrics/article/153/2/e2023065044/195490/Recommended-Childhood-and-Adolescent-Immunization
Retrieved from "https://aaushi.info/w/index.php?title=A6085&oldid=1192551"